Defensins in Clinical Development: From Lab to Pharmacy

Defensins are among the oldest weapons in the human immune arsenal. These small, cysteine-rich peptides have protected organisms from microbial invaders for hundreds of millions of years. Now, pharmaceutical researchers are attempting something ambitious: turning these ancient defense molecules into modern drugs.

The path from naturally occurring defensin to pharmacy shelf has been slower than anyone hoped. But the picture is changing. Brilacidin, a synthetic defensin mimetic, has completed multiple Phase 2 trials across four different indications. Recombinant human beta-defensin 2 (hBD-2) is being developed for immune disorders. And a new generation of defensin-inspired peptidomimetics is targeting the bacteria that conventional antibiotics can no longer reach.

Here is where defensin drug development stands today, what separates the leading candidates, and what still needs to happen for defensin-based therapies to reach patients.

Defensins 101: Alpha vs. Beta

Before diving into clinical programs, it helps to understand what makes defensins unique -- and why the alpha and beta subtypes matter for drug development.

All human defensins share a core structural feature: six cysteine residues that form three disulfide bonds, creating a rigid beta-sheet scaffold. This locked structure gives defensins unusual stability compared to other antimicrobial peptides and is partly why they have attracted pharmaceutical interest.

Alpha-Defensins (HNP-1 through HNP-4, HD5, HD6)

Human neutrophil peptides (HNP-1 through HNP-4) are stored in neutrophil granules and released during infection. They kill bacteria primarily through membrane disruption. HNP-1 alone accounts for 30-50% of the protein content in neutrophil azurophilic granules -- a sign of how important these peptides are to immune defense.

Human defensins 5 and 6 (HD5 and HD6) are produced by intestinal Paneth cells. HD5 is a potent broad-spectrum antimicrobial that kills both gram-positive and gram-negative bacteria. HD6 takes a completely different approach: instead of directly killing bacteria, it self-assembles into "nanonets" -- fibrillar structures that physically trap and contain microbes in the gut lumen.

Beta-Defensins (hBD-1 through hBD-4)

Beta-defensins are produced by epithelial cells throughout the body -- skin, airways, urogenital tract, and gut. Of the four major human beta-defensins:

hBD-1 is constitutively expressed (always on) and provides baseline protection
hBD-2 is induced by bacterial contact and inflammatory signals
hBD-3 has the broadest antimicrobial spectrum, including activity against MRSA even in high-salt environments
hBD-4 is the least studied but appears active against gram-negative bacteria and yeast

For drug development purposes, the key difference between alpha and beta defensins is their disulfide bond connectivity. Alpha-defensins pair cysteines 1-6, 2-4, and 3-5. Beta-defensins pair cysteines 1-5, 2-4, and 3-6. This seemingly minor structural distinction affects their stability, mechanism of action, and how easy they are to manufacture.

For drug development purposes, the key difference between alpha and beta defensins is their disulfide bond connectivity. But there are also functional distinctions that matter therapeutically:

Alpha-defensins are primarily stored and released from immune cells (neutrophils, Paneth cells), making them "on-demand" antimicrobials
Beta-defensins are produced at epithelial surfaces (skin, airways, gut lining) and provide continuous barrier defense
Alpha-defensins tend to be more potent killers but less stable outside the body
Beta-defensins are more stable but generally require higher concentrations for direct killing

These differences shape which defensin subtypes are most promising for different therapeutic applications. For wound care and topical infections, beta-defensins (especially hBD-3) lead. For gut-targeted therapies, alpha-defensins (especially HD5) are more relevant.

For a broader overview of the defensin family, see our complete guide.

Brilacidin: The Furthest Along

Brilacidin (PMX-30063) is not a defensin. It is a defensin mimetic -- a small synthetic molecule designed to reproduce the antimicrobial activity of host defense peptides like defensins without being a peptide itself. Developed by Innovation Pharmaceuticals, it is a 936.9 g/mol compound that mimics the amphipathic, cationic structure of defensins using a non-peptide scaffold.

This distinction matters enormously for drug development. Being a small molecule rather than a peptide, brilacidin avoids many of the manufacturing and stability challenges that plague natural defensin drug candidates.

Clinical Trial Track Record

Brilacidin has been tested in over 500 human subjects across multiple indications:

Acute Bacterial Skin and Skin Structure Infection (ABSSSI). A Phase 2b trial found that a single intravenous dose of brilacidin was comparable in safety and efficacy to a 7-day course of daptomycin -- an already-approved lipopeptide antibiotic. The FDA granted brilacidin Qualified Infectious Disease Product (QIDP) designation, qualifying it for Fast Track review, Priority Review, and an extra 5 years of market exclusivity upon approval.

Oral Mucositis. Cancer patients receiving chemoradiation for head and neck cancer often develop severe mouth sores (oral mucositis) that can delay treatment. In a Phase 2 trial under FDA Fast Track designation, brilacidin oral rinse showed a clear reduction in severe oral mucositis compared to placebo. The FDA and Innovation Pharmaceuticals have agreed on an acceptable Phase 3 development pathway.

Ulcerative Proctitis/Proctosigmoiditis. In a proof-of-concept Phase 2 trial, a majority of patients treated with brilacidin achieved clinical remission. These results led Italian pharmaceutical company Alfasigma S.p.A. to license brilacidin for this inflammatory bowel disease indication.

COVID-19. Brilacidin received FDA Fast Track for COVID-19 and was evaluated in a placebo-controlled Phase 2 trial. The primary endpoint (time to sustained recovery by Day 29) was not met overall, but patients who began treatment within 7 days of symptom onset recovered more quickly.

Expanding Antimicrobial Portfolio

Beyond its clinical indications, brilacidin's preclinical profile continues to grow.

Multidrug-resistant gonorrhea. A 2025 PLOS One study tested brilacidin against 22 drug-resistant Neisseria gonorrhoeae strains. It inhibited 50% of strains (MIC50) at 4 micrograms per milliliter and showed rapid bactericidal activity, reducing high-inoculum N. gonorrhoeae within two hours. It outperformed ceftriaxone -- the current standard of care -- at eliminating intracellular N. gonorrhoeae inside endocervical cells.

Fungal infections. Published in Nature Communications (2023), brilacidin synergizes with caspofungin against drug-resistant Aspergillus fumigatus, Candida albicans, C. auris, and caspofungin-resistant Cryptococcus neoformans. In immunosuppressed mice, the brilacidin-caspofungin combination significantly cleared A. fumigatus lung infection. Brilacidin alone showed activity against 13 of 19 WHO priority fungal pathogens.

Antiviral activity. Brilacidin blocks SARS-CoV-2 infection by preventing viral entry, with activity against multiple variants.

What Makes Brilacidin Different

Brilacidin works like the antimicrobial peptides it mimics but solves several of their core problems. As a non-peptide small molecule, it resists protease degradation, is cheaper to manufacture, and has better pharmacokinetic properties. It represents proof of concept that defensin-inspired drugs can be commercially viable.

The trajectory of brilacidin also illustrates something important about the antimicrobial peptide field more broadly: the most clinically advanced candidates are not natural peptides at all. They are synthetic molecules inspired by natural peptides. This may be the route defensin biology takes to the pharmacy -- through mimicry rather than direct translation.

Brilacidin's Competitive Position

Brilacidin holds a unique position in the AMP field. It is the only defensin-mimetic compound with Phase 2 data across four indications, QIDP designation, and an agreed Phase 3 pathway. For skin infections, it competed favorably against daptomycin -- an already-approved drug -- in a head-to-head comparison. For oral mucositis, it has no direct AMP competitor.

The key question is whether Innovation Pharmaceuticals can secure the funding and partnerships needed to complete Phase 3 trials. The oral mucositis program has the clearest path to registration, given FDA agreement on trial design and the unmet medical need (there is no approved drug for prevention of oral mucositis in head and neck cancer patients receiving chemoradiation).

Defensin Therapeutics and Recombinant hBD-2

While brilacidin mimics defensin function through synthetic chemistry, Defensin Therapeutics ApS -- a Danish biopharmaceutical company spun out from Novozymes in 2013 -- is developing the real thing: recombinant human beta-defensin 2 (hBD-2).

The Science Behind hBD-2 Therapy

hBD-2 is an inducible defensin that the body produces in response to bacterial contact and inflammation. Beyond its direct antimicrobial activity, hBD-2 is a potent immunomodulator. It recruits dendritic cells, T cells, and mast cells to infection sites and helps shape the adaptive immune response.

Defensin Therapeutics is exploiting this immunomodulatory role for diseases where the immune system is the problem rather than infection itself.

Graft-versus-Host Disease (GvHD)

In a study published in Science Translational Medicine, researchers at the University of Freiburg found that hBD-2 administration significantly improved disease severity and mortality in mice with acute GvHD -- the life-threatening condition where transplanted immune cells attack the recipient's body. This finding positions hBD-2 as a potential therapy for one of the most serious complications of bone marrow transplantation.

Where hBD-2 Development Stands

Defensin Therapeutics uses a recombinant polypeptide platform for production. Specific clinical trial timelines are not publicly available, but the company's pipeline targets immune system diseases where hBD-2's immunomodulatory properties can be leveraged.

For comparison with other immune-modulating peptides, see our profiles on Thymosin Alpha-1 and our TA1 vs. LL-37 comparison.

HD5-Inspired Peptidomimetics: A New Wave

Human alpha-defensin 5 (HD5) is one of the most potent natural antimicrobial peptides produced in the human gut. Researchers at PNAS (Proceedings of the National Academy of Sciences) reported the development of peptidomimetic antibiotics derived from HD5 that engage multiple bacterial targets simultaneously.

The lead compound is effective both in vitro and in vivo against bacteria with highly inducible antibiotic resistance. By engaging multiple targets rather than a single one, these HD5-inspired compounds reduce the chance of resistance development -- addressing a critical weakness of conventional antibiotics.

Why Not Just Use Natural HD5?

Three major problems hold back natural HD5 as a drug:

Insufficient raw potency for clinical therapeutic requirements
Activity inhibited by serum and physiological salt concentrations -- the same salt levels found in blood and tissue fluids reduce HD5's effectiveness
Large size and complex structure that makes chemical modification and synthesis difficult

The peptidomimetic approach preserves HD5's multi-target mechanism while engineering around these limitations -- a strategy that has produced promising preclinical results.

Alpha-Defensins as Diagnostics

Not all defensin clinical development involves therapeutics. Alpha-defensin has found an unexpected second career as a diagnostic biomarker.

When neutrophils encounter bacteria in joint fluid, they release alpha-defensin into the synovial space. This makes alpha-defensin a highly specific marker for periprosthetic joint infection (PJI) -- the dreaded complication where bacteria colonize artificial hip or knee replacements.

Two commercial test formats are now available:

Alpha-defensin ELISA (laboratory-based)
Alpha-defensin lateral flow test (point-of-care, rapid results)

A 2025 systematic review and meta-analysis confirmed favorable sensitivity and specificity for both formats. Importantly, alpha-defensin is more specific to true infection than conventional markers like CRP or ESR, which can be elevated by sterile inflammation. The alpha-defensin lateral flow test is FDA-approved for evaluation of infection in both native and prosthetic joints.

Defensins in Dermatology

A separate track of defensin clinical development targets skin aging and repair -- an application that might seem surprising for antimicrobial peptides but makes biological sense.

Defensins recruit Lgr6-positive stem cells, which regenerate basal stem cells, healthy keratinocytes, and new hair follicles. In a multicenter clinical trial of 20 subjects aged 45-80, a skincare regimen containing alpha-defensin 5 and beta-defensin 3 applied twice daily for 12 weeks produced statistically significant improvement in both wrinkling and elastosis on the Fitzpatrick-Goldman wrinkle scale. At the 90-day follow-up, 30% of subjects were rated "much improved" and 50% were rated "improved."

An earlier double-blind, vehicle-controlled trial confirmed that a three-product defensin skincare regimen increased epidermal thickness, reduced wrinkle appearance, reduced pore visibility, and decreased melanin -- consistent with the hypothesis that defensins activate dormant stem cells to generate healthy new epidermal cells.

For more on peptide applications in skin health, see our guides on peptide skincare for acne-prone skin and peptides for acne and skin healing.

The Manufacturing Challenge

Why aren't there more defensin drugs? A large part of the answer is manufacturing economics.

Natural defensins have three disulfide bonds that must form correctly for the peptide to fold into its active structure. Incorrect disulfide pairing produces inactive or toxic misfolded products. Chemical synthesis of a properly folded defensin is technically feasible but expensive -- production costs can reach tens of thousands of dollars per gram for research-grade material.

Recombinant production in bacteria is cheaper but comes with its own problems. A study comparing production of HD5 and bovine LAP defensin in E. coli found that strain selection profoundly affected yields -- HD5 production was significantly higher in BL21 than in Origami B strains. The fusion protein approach, where defensins are produced as part of a larger protein to protect host cells from the peptide's toxicity, adds purification steps and cost.

The defensin-mimetic approach (exemplified by brilacidin) sidesteps these issues entirely by using synthetic small molecules instead of actual peptides. This is why defensin mimetics are further along clinically than recombinant defensins.

Scale and Cost Numbers

To put the manufacturing challenge in perspective: chemical synthesis of a properly folded defensin can cost upward of $41,000 per gram at research scale. Recombinant production in E. coli or yeast reduces this substantially but remains more expensive than small-molecule antibiotic manufacturing. The antibacterial active peptide market overall reached $8.49 billion in 2024 and is projected to grow to $17.84 billion by 2033 at an 8.6% compound annual growth rate -- suggesting the economics are improving, but slowly.

Over 55% of peptide companies now use recombinant technology for production, and optimized yeast systems (Komagataella phaffii) have boosted defensin expression yields by over 34% compared to standard fermentation. For defensins specifically, the fusion protein approach in E. coli remains the most common production method, where the defensin is expressed as part of a larger protein to protect the host cell from the peptide's antimicrobial activity during production.

What Comes Next

The defensin drug pipeline is thin compared to conventional antibiotic development, but several trends point toward acceleration:

AI-driven defensin design. Machine learning models trained on defensin structure-activity relationships can now generate novel defensin-inspired sequences optimized for potency, selectivity, and manufacturability. These tools compress the discovery timeline from years to months.

Defensin-functionalized materials. A 2025 study in Communications Materials (Nature) demonstrated defensin-conjugated polymer fabrics that prevent bacterial adhesion and biofilm formation while promoting wound healing -- pointing toward applications in wound dressings and medical device coatings rather than systemic drugs.

Combination strategies. Defensin-derived drugs may reach patients faster as combination partners with existing antibiotics rather than as standalone therapies. Brilacidin's synergy with caspofungin and ceftriaxone provides a template.

Topical-first approach. Given the challenges of systemic delivery, the first wave of defensin therapeutics will likely target local applications: wound infections, skin conditions, oral mucositis, and inhaled treatments for lung infections. This is already the trajectory for brilacidin's most advanced programs.

Anti-biofilm applications. hBD-3 shows dose-dependent inhibition of staphylococcal biofilms on titanium implant surfaces, making defensin-based coatings a promising approach for preventing prosthetic joint infections and other implant-associated biofilm diseases. LL-37 and defensins together form a potent anti-biofilm combination in the wound environment. For more on this topic, see our biofilm disruption research article.

Timeline and Probability Assessment

Where are defensin drugs most likely to reach patients first? Based on the current pipeline:

Brilacidin for oral mucositis -- Highest probability near-term. Phase 3 pathway agreed with FDA. Clear unmet medical need. Topical delivery avoids systemic challenges. Estimated timeline: 3-5 years if Phase 3 is funded and executed.
Brilacidin for skin infections -- Strong Phase 2 data, QIDP designation. But the competitive field (including approved drugs like daptomycin and vancomycin) makes the regulatory bar higher. Phase 3 would need to demonstrate superiority or significant convenience advantage.
Defensin-conjugated wound materials -- Preclinical stage, but the regulatory pathway for medical devices is potentially faster than drug approval. A defensin-coated wound dressing classified as a device could reach market before a defensin drug.
Recombinant hBD-2 for immune disorders -- Longer timeline. GvHD animal data is promising but early. The regulatory pathway for an immunomodulatory peptide biologic is complex.
HD5-inspired peptidomimetic antibiotics -- Earliest stage. Multi-target mechanism is promising for resistant infections but needs extensive safety and efficacy data.

The Bottom Line

Defensins have been protecting humans from infection since before we were human. Turning them into drugs has taken longer than anticipated, but the clinical evidence is building. Brilacidin has demonstrated that defensin-mimetic compounds can be safe, effective, and manufacturable at scale. Recombinant hBD-2 is opening doors in immunology. And HD5-inspired peptidomimetics are attacking drug-resistant bacteria through mechanisms that conventional antibiotics cannot.

The gap between defensin biology and defensin pharmacology is closing. Whether the first defensin-derived drug to reach wide clinical use is a mimetic like brilacidin, a recombinant peptide, or a peptidomimetic inspired by HD5, the defensin family is positioning itself as a serious contender in the fight against antimicrobial resistance.

Related Reading on PeptideJournal.org: